TRA2A (transformer 2 alpha homolog) is a sequence-specific RNA-binding protein that regulates pre-mRNA splicing and plays critical roles in cancer progression and disease pathogenesis 1. In cancer contexts, TRA2A promotes tumor progression through multiple mechanisms: it facilitates proliferation, migration, invasion, and epithelial-mesenchymal transition in glioma cells 2, and drives paclitaxel resistance in triple-negative breast cancer by controlling alternative splicing of cancer-related genes like RSRC2 1. TRA2A also contributes to metastatic prostate cancer by promoting M2-tumor-associated macrophage infiltration through IL32 splicing regulation 3. Beyond its canonical splicing function, TRA2A exhibits noncanonical roles in lncRNA regulation, coordinating with methylation proteins to promote oncogenic MALAT1 stability in esophageal cancer 4. In viral infections, TRA2A determines influenza A virus host adaptation by regulating viral mRNA splicing differently for avian versus human strains 5. TRA2A is clinically significant as it correlates with poor prognosis across multiple cancer types and represents a potential therapeutic target. Its overexpression is associated with advanced pathological progression and chemotherapy resistance, making it valuable for clinical treatment decisions and patient outcome prediction 12.